TWI711464B - 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法 - Google Patents

預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法 Download PDF

Info

Publication number
TWI711464B
TWI711464B TW105110295A TW105110295A TWI711464B TW I711464 B TWI711464 B TW I711464B TW 105110295 A TW105110295 A TW 105110295A TW 105110295 A TW105110295 A TW 105110295A TW I711464 B TWI711464 B TW I711464B
Authority
TW
Taiwan
Prior art keywords
liver
mannitol
fatty liver
combination
sucralose
Prior art date
Application number
TW105110295A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718015A (zh
Inventor
胡幼圃
何欣恬
吳永恩
唐熙卉
Original Assignee
欣耀生醫股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 欣耀生醫股份有限公司 filed Critical 欣耀生醫股份有限公司
Publication of TW201718015A publication Critical patent/TW201718015A/zh
Application granted granted Critical
Publication of TWI711464B publication Critical patent/TWI711464B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/733—Compounds of undetermined constitution obtained from animals or plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
TW105110295A 2015-11-19 2016-03-31 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法 TWI711464B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257697P 2015-11-19 2015-11-19
US62/257,697 2015-11-19

Publications (2)

Publication Number Publication Date
TW201718015A TW201718015A (zh) 2017-06-01
TWI711464B true TWI711464B (zh) 2020-12-01

Family

ID=58718029

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105110295A TWI711464B (zh) 2015-11-19 2016-03-31 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法

Country Status (7)

Country Link
US (1) US10925854B2 (enExample)
EP (1) EP3391881A4 (enExample)
JP (4) JP2018534323A (enExample)
CN (2) CN107613968A (enExample)
HK (1) HK1244213A1 (enExample)
TW (1) TWI711464B (enExample)
WO (1) WO2017084234A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4609911A3 (en) * 2015-09-24 2025-11-19 Sinew Pharma Inc. Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
CN110151787A (zh) * 2018-02-12 2019-08-23 玛旺干细胞医学生物科技股份有限公司 护肝组合物及其用途
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
WO2020262703A1 (ja) * 2019-06-25 2020-12-30 独立行政法人国立病院機構 タキシフォリンを含有する肝線維化抑制剤及び褐色脂肪細胞活性化剤
CN112471376A (zh) * 2020-11-02 2021-03-12 辽宁康汇医学临床研究有限公司 一种防治酒精性脂肪肝的固体饮料及其制备方法
CN113440514B (zh) * 2021-08-20 2022-09-09 中国农业科学院郑州果树研究所 含橙皮素的组合物及其制备降血糖药物的应用
CN116333965A (zh) * 2022-12-30 2023-06-27 重庆大学附属三峡医院 一种葛根外泌体样纳米颗粒及其制备方法和应用
CN117205159A (zh) * 2023-09-04 2023-12-12 中国医学科学院药用植物研究所 一种自纳米组合物及制备方法与应用
CN119184297A (zh) * 2024-09-18 2024-12-27 中国农业大学 葛根素及其衍生物调控des1改善肝脏脂质堆积及其应用
CN120732881B (zh) * 2025-09-03 2026-05-08 山东第一医科大学(山东省医学科学院) 金丝桃苷和丹酚酸b联合制备治疗nafld药物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140038921A1 (en) * 2011-04-20 2014-02-06 National Defense Education And Research Foundation New low side effect pharmaceutical composition containing antituberculosis drugs
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388328A (en) * 1981-10-15 1983-06-14 Warner-Lambert Company Sorbitol containing mixture encapsulated flavor
US5080910A (en) * 1990-05-15 1992-01-14 Werner-Lambert Company Stabilized chlorodeoxysugar sweetening agents in powder form and methods for preparing same
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
CA2328357A1 (en) * 1998-04-16 1999-10-28 The City Of Osaka Therapeutic agent for primary biliary cirrhosis
JP4824886B2 (ja) * 2001-09-11 2011-11-30 長岡香料株式会社 フルクトース吸収阻害剤、組成物、および食品
JP4203282B2 (ja) * 2002-08-26 2008-12-24 株式会社青粒 アブラナ科植物の抽出物とその用途
JP4893981B2 (ja) * 2003-04-03 2012-03-07 株式会社林原生物化学研究所 脂質調節剤及びその用途
JPWO2006135084A1 (ja) * 2005-06-14 2009-01-08 学校法人 久留米大学 脂肪性肝炎または脂肪肝の予防または治療薬
JP2007182405A (ja) * 2006-01-10 2007-07-19 Univ Kurume 脂肪性肝疾患の改善治療薬
WO2009028457A1 (ja) * 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
CN101683411B (zh) * 2008-09-24 2012-09-19 汪鋆植 海棠提取物在制备保肝药物或保健食品中的用途
CN101744865B (zh) * 2008-12-18 2012-07-25 山东福田药业有限公司 一种木糖醇护肝片的制备方法
JP2012520866A (ja) * 2009-03-17 2012-09-10 アプタリス・ファーマ・カナダ・インコーポレイテッド 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法
TR200904862A1 (tr) * 2009-05-29 2010-12-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Sukraloz formülasyonu ve üretim prosesi
CN101933900A (zh) * 2009-07-02 2011-01-05 天津瑞普生物技术股份有限公司 一种用于防治禽类肝病的复方制剂及其制备方法
JP2011231078A (ja) * 2010-04-30 2011-11-17 Nagaoka Koryo Kk 非アルコール性脂肪性肝疾患の予防および／または治療に有効な経口摂取用組成物
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
CN102908596B (zh) 2011-08-05 2014-09-03 成都永康制药有限公司 一种治疗脂肪肝的中药组合物
US9675699B2 (en) * 2011-12-22 2017-06-13 International Flavors & Fragrances Inc. Cooling enhancing compositions
US20140274979A1 (en) * 2013-03-13 2014-09-18 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
US10441560B2 (en) * 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN105143428B (zh) * 2013-04-29 2017-08-25 哈沙·奇古鲁帕蒂 酒精饮料中降低的毒性
CN103432528A (zh) 2013-08-23 2013-12-11 冯庄明 一种治疗非酒精性脂肪肝的中药制剂
EP4609911A3 (en) * 2015-09-24 2025-11-19 Sinew Pharma Inc. Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140038921A1 (en) * 2011-04-20 2014-02-06 National Defense Education And Research Foundation New low side effect pharmaceutical composition containing antituberculosis drugs
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合

Also Published As

Publication number Publication date
JP2021105037A (ja) 2021-07-26
CN107613968A (zh) 2018-01-19
US20180117003A1 (en) 2018-05-03
JP2025124769A (ja) 2025-08-26
EP3391881A4 (en) 2020-03-11
JP2018534323A (ja) 2018-11-22
TW201718015A (zh) 2017-06-01
US10925854B2 (en) 2021-02-23
JP2023145714A (ja) 2023-10-11
JP7690526B2 (ja) 2025-06-10
HK1244213A1 (zh) 2018-08-03
WO2017084234A1 (zh) 2017-05-26
CN116440143A (zh) 2023-07-18
EP3391881A1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
JP7690526B2 (ja) 脂肪肝の予防または処置用医薬組成物
Cao et al. Quercetin ameliorates nonalcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy
Ye et al. Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis
Li et al. Fenretinide attenuates lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) and depressive-like behavior in mice by targeting Nrf-2 signaling
Zeng et al. l-Theanine attenuates liver aging by inhibiting advanced glycation end products in d-galactose-induced rats and reversing an imbalance of oxidative stress and inflammation
Yuan et al. Protective effect of resveratrol on kidney in rats with diabetic nephropathy and its effect on endoplasmic reticulum stress.
Ahn et al. Hepatoprotective effects of Lycium chinense Miller fruit and its constituent betaine in CCl4-induced hepatic damage in rats
Zhang et al. Urolithin A, a pomegranate metabolite, protects pancreatic β cells from apoptosis by activating autophagy
Park et al. Narirutin fraction from citrus peels attenuates alcoholic liver disease in mice
Yan et al. Panax notoginsenoside saponins Rb1 regulates the expressions of Akt/mTOR/PTEN signals in the hippocampus after focal cerebral ischemia in rats
Sun et al. Baicalin and N-acetylcysteine regulate choline metabolism via TFAM to attenuate cadmium-induced liver fibrosis
Wang et al. 6′-O-Caffeoylarbutin from Que Zui tea ameliorates acetaminophen-induced liver injury via enhancing antioxidant ability and regulating the PI3K signaling pathway
Zhou et al. Schisandrin B inhibits inflammation and ferroptosis in S. aureus-induced mastitis through regulating SIRT1/p53/SLC7A11 signaling pathway
Hu et al. Nicotinic acid against acetaminophen-induced hepatotoxicity via Sirt1/Nrf2 antioxidative pathway in mice
WO2016026139A1 (zh) 用于治疗非酒精性脂肪肝疾病的药物及应用
Rodniem et al. Protective effect of alpha-mangostin on thioacetamide-induced liver fibrosis in rats as revealed by morpho-functional analysis
CN118178446A (zh) 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用
Sun et al. Gastroprotective effect of fucoidan from Sargassum siliquastrum against ethanol-induced gastric mucosal injury
Rong et al. Melatonin: a novel strategy for prevention of obesity and fat accumulation in peripheral organs through the improvements of circadian rhythms and antioxidative capacity
Chen et al. Gypensapogenin I alleviates PANoptosis, ferroptosis, and oxidative stress in myocardial ischemic–reperfusion injury by targeting the NOX2/AMPK pathway
TWI634886B (zh) Compound composition for liver-free side effects with reduced liver fat for treating symptoms of non-alcoholic fatty liver disease (NAFLD)
KR20150130352A (ko) 지방간 질환을 치료하는 방법
HK40089284A (en) Pharmaceutical composition for preventing or treating fatty liver
WO2013127110A1 (zh) 汉黄芩素在制备治疗慢性肾病的药物中的用途
Wang et al. Theaflavins, theaflavin-3, 3′-digallate, and its nanoparticles attenuate chronic alcohol-induced gastric injury and hepatic fibrosis by activating the AMPK/mTOR/Beclin1/LC3 autophagy pathway and modulating intestinal microbiota in ICR mice